Characteristics | ORR, No. (%) | *p-value | gOR (95% CI), p-value | DCR, No. (%) | *p-value | gOR (95% CI), p-value |
---|---|---|---|---|---|---|
EGFR mutation subtype, No. (%) | ||||||
 Exon 19 deletion | 52 (76.5) | 0.265 | 2.27 (0.47–11.01), 0.309a | 64 (94.1) | 0.263 | 2.72 (0.41–18.24), 0.302a |
 Exon 21 L858R point mutation | 6 (54.5) |  | 0.40 (0.03–5.21), 0.485b | 9 (81.8) |  | 2.28 (0.31–16.62), 0.420b |
 Rare and complex mutation | 5 (83.3) |  |  | 6 (100) |  |  |
Baseline symptomatic brain metastases, No. (%) | ||||||
 No | 49 (81.7) | 0.014 | 4.51 (1.45–14.00), 0.009# | 57 (95.0) | 0.251 | 3.0 (0.55–16.38), 0.205# |
 Yes | 14 (56.0) |  |  | 22 (88.0) |  |  |
ECOG performance status, No. (%) | ||||||
 0–1 | 49 (71.0) | 0.175 | 0.27 (0.05–1.44), 0.125# | 64 (92.8) | 0.889 | 0.79 (0.08–8.76), 0.835# |
 2–4 | 14 (87.5) |  |  | 15 (93.8) |  |  |
Abnormal organ function, No. (%) | ||||||
 No | 53 (75.7) | 0.468 | 1.27 (0.28–5.81), 0.755# | 64 (91.4) | 0.585 | 0.57 (0.07–4.97), 0.616 # |
 Yes | 10 (66.7) |  |  | 15 (100) |  |  |
Afatinib dose adjustment, No. (%) | ||||||
 Dose reduced | 23 (88.5) | 0.084 | 5.53 (1.32–23.24), 0.019c | 25 (96.2) | 0.729 | 3.22 (0.29–35.40), 0.339c |
 Dose increased | 8 (80.0) |  | 2.13 (0.36–12.57), 0.404d | 9 (90.0) |  | 1.30 (0.11–15.02), 0.835d |
 Starting dose maintained | 32 (65.3) |  |  | 45 (91.8) |  |  |
Optimal afatinib dose, No. (%) | ||||||
 Less than 40 mg once daily | 40 (78.4) | 0.156 | 2.03 (0.59–6.94), 0.259e | 47 (92.2) | 0.836 | 0.88; 0.13–6.13, 0.895e |
 40 mg once daily | 19 (63.3) |  |  | 28 (29.3) |  |  |
 50 mg once daily | 4 (100)f |  |  | 4 (100)f |  |  |